Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3134]

ASH 2022: Talquetamab generates high response rate in patients with hard-to-treat multiple myeloma

ASH 2022: Talquetamab generates high response rate in patients with hard-to-treat multiple myeloma

ASH 2022: Extending chemotherapy slashes risk of aggressive childhood leukaemia coming back

ASH 2022: Extending chemotherapy slashes risk of aggressive childhood leukaemia coming back

$FDA approves olutasidenib for relapsed or refractory acute myeloid leukaemia with a susceptible IDH1 mutation$

FDA approves olutasidenib for relapsed or refractory acute myeloid leukaemia with a susceptible IDH1 mutation

How AI found the words to kill cancer cells

How AI found the words to kill cancer cells

Hospital parking fees contribute to financial toxicity for cancer patients

Hospital parking fees contribute to financial toxicity for cancer patients

European Commission approves zanubrutinib for the treatment of adults with marginal zone lymphoma

European Commission approves zanubrutinib for the treatment of adults with marginal zone lymphoma

Discovery suggests new way to target mantle cell lymphoma

Discovery suggests new way to target mantle cell lymphoma

FDA approves a new dosing regimen for asparaginase erwinia chrysanthemi (recombinant)

FDA approves a new dosing regimen for asparaginase erwinia chrysanthemi (recombinant)

European Commission approves zanubrutinib for the treatment of adults with chronic lymphocytic leukaemia

European Commission approves zanubrutinib for the treatment of adults with chronic lymphocytic leukaemia

FDA approves brentuximab vedotin in combination with chemotherapy for paediatric patients with classical Hodgkin lymphoma

FDA approves brentuximab vedotin in combination with chemotherapy for paediatric patients with classical Hodgkin...

More from ecancer